Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Children’s Hospital Resumes FDA-Funded Study Of PEG 3350 Pediatric Risks

Executive Summary

New FDA assays may show whether polyethylene glycol laxative leaves toxic analytes and metabolites in children with chronic constipation – with potential implications for numerous other products.

You may also be interested in...



FDA Global Supply Chain Concerns Prompt Glycerin DEG Testing Guidance

Pharmaceutical manufacturing facilities and compounding pharmacists should include tests for diethylene glycol content in the identity testing of all lots of glycerin they receive, according to an FDA guidance reflecting growing concern about vulnerabilities in the global supply chain

ICMRA’s Pilot On Hybrid Inspections And CMC Changes Seeks Participants

Driven by COVID-19 pandemic challenges, regulatory authorities from multiple regions want to work with sponsors on new joint approaches for expediting manufacturing changes globally and streamlining preapproval and pre-licensing inspections.

US FDA Would Allow Separation Alternatives In Manufacture Of Low-Risk Beta-Lactams

Proposed guidance revision adds nuance to manufacturing facility separation expectations for beta-lactam compounds that pose less risk of anaphylaxis than penicillin and related antibiotics.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS144260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel